Alicia Ponte-Sucre

Dr. Alicia Ponte-Sucre

orcid

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2017 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
APAlicia Ponte-Sucre
Alicia Ponte-Sucre
FGFrancisco Gamarro
Francisco Gamarro
JDJean-Claude Dujardin
Jean-Claude Dujardin
MBMichael P. Barrett
Michael P. Barrett
RLRogelio López-Vélez
Rogelio López-Vélez
BPBarbara Papadopoulou
Barbara Papadopoulou
Reevaluation of treatment guidelines for Old and New World leishmaniasis is urgently needed on a global basis because treatment failure is an increasing problem. Drug resistance is a fundamental determinant of treatment failure, although other factors also contribute to this phenomenon, including the global HIV/AIDS epidemic with its accompanying impact on the immune system. Pentavalent antimonials have been used successfully worldwide for the treatment of leishmaniasis since the first half of the 20th century, but the last 10 to 20 years have witnessed an increase in clinical resistance, e.g., in North Bihar in India. In this review, we discuss the meaning of “resistance” related to leishmaniasis and discuss its molecular epidemiology, particularly for Leishmania donovani that causes visceral leishmaniasis. We also discuss how resistance can affect drug combination therapies. Molecular mechanisms known to contribute to resistance to antimonials, amphotericin B, and miltefosine are also outlined. Chemotherapy is central to the control and management of leishmaniasis. Antimonials remain the primary drugs against different forms of leishmaniasis in several regions. However, resistance to antimony has necessitated the use of alternative medications, especially in the Indian subcontinent (ISC). Compounds, notably the orally available miltefosine (MIL), parenteral paromomycin, and amphotericin B (AmB), are increasingly used to treat leishmaniasis. Although treatment failure (TF) has been observed in patients treated with most anti-leishmanials, its frequency of appearance may be important in patients treated with MIL, which has replaced antimonials within the kala-azar elimination program in the ISC. AmB is highly efficacious, and the associated toxic effects—when administered in its free deoxycholate form—are somewhat ameliorated in its liposomal formulation. Regrettably, laboratory experimentation has demonstrated a risk of resistance towards AmB as well. The rise of drug resistance impacts treatment outcome, and understanding its causes, spread, and impact will help us manage the risks it imposes. Here, we review the problem of TF in leishmaniasis and the contribution of drug resistance to the problem. Molecular mechanisms causing resistance to anti-leishmanials are discussed along with the appropriate use of additional available drugs, as well as the urgent need to consolidate strategies to monitor drug efficacy, epidemiological surveillance, and local policies. Coordination of these activities in national and international programs against leishmaniasis might represent a successful guide to further research and prevention activities.

1 June 2007 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
SNSonimar Natera
Sonimar Natera
CMClaudia Machuca
Claudia Machuca
MPMaritza Padrón-Nieves
Maritza Padrón-Nieves
ARAmarilis Romero
Amarilis Romero
EDEmilia Díaz
Emilia Díaz
APAlicia Ponte-Sucre
Alicia Ponte-Sucre

26 December 2016 in Frontiers in Microbiology
Verified
Journal Article
Open access
APAlicia Ponte-Sucre
Alicia Ponte-Sucre
T. brucei rhodesiense and T. brucei gambiense, the causative agents of Human African Trypanosomiasis (HAT), are transmitted by tsetse flies. Within the vector, the parasite undergoes through transformations that prepares it to infect the human host. Sequentially these developmental stages are the replicative procyclic (in which the parasite surface is covered by procyclins) and trypo-epimastigote forms, as well as the non-replicative, infective, metacyclic form that develops in the vector salivary glands. As a pre-adaptation to their life in humans, metacyclic parasites begin to express and be densely covered by the Variant Surface Glycoprotein (VSG). Once the metacyclic form invades the human host the parasite develops into the bloodstream form. Herein the VSG triggers a humoral immune response. To avoid this humoral response, and essential for survival while in the bloodstream, the parasite changes its cover periodically and sheds into the surroundings the expressed VSG, thus evading the consequences of the immune system activation. Additionally, tools comparable to quorum sensing are used by the parasite for the successful parasite transmission from human to insect. On the other hand, the human host promotes clearance of the parasite triggering innate and adaptive immune responses and stimulating cytokine and chemokine secretion. All in all, the host-parasite interaction is extremely active and leads to responses that need multiple control sites to develop appropriately.

6 May 2014 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
MVManu Vanaerschot
Manu Vanaerschot
Franck A DumetzFranck A Dumetz
Franck A Dumetz
SRSyamal Roy
Syamal Roy
APAlicia Ponte-Sucre
Alicia Ponte-Sucre
JAJorge Arevalo
Jorge Arevalo
JDJean-Claude Dujardin
Jean-Claude Dujardin
Two major leishmaniasis treatments have shown a significant decrease in effectiveness in the last few decades, mostly in the Indian subcontinent but also in other endemic areas. Drug resistance of Leishmania correlated only partially to treatment failure (TF) of pentavalent antimonials, and has so far proved not to be important for the increased miltefosine relapse rates observed in the Indian subcontinent. While other patient- or drug-related factors could also have played a role, recent studies identified several parasite features such as infectivity and host manipulation skills that might contribute to TF. This perspective aims to discuss how different parasitic features other than drug resistance can contribute to TF of leishmaniasis and how this may vary between different epidemiological contexts.

16 November 2006 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
GBGerhard Bringmann
Gerhard Bringmann
IKInga Kajahn
Inga Kajahn
MRMatthias Reichert
Matthias Reichert
SPSarah E. H. Pedersen
Sarah E. H. Pedersen
JFJohan H. Faber
Johan H. Faber
VMVirima Mudogo
Virima Mudogo

1 May 2006 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
RVRadim Vicik
Radim Vicik
VHVerena Hoerr
Verena Hoerr
MGMelanie Glaser
Melanie Glaser
MSMartina Schultheis
Martina Schultheis
EHElizabeth Hansell
Elizabeth Hansell
TSTanja Schirmeister
Tanja Schirmeister